MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Novo Nordisk A-S

Cerrado

SectorSalud

68.14 0.29

Resumen

Variación precio

24h

Actual

Mínimo

67.3

Máximo

68.69

Métricas clave

By Trading Economics

Ingresos

929M

28B

Ventas

14B

86B

P/B

Media del Sector

21.171

63.778

BPA

6.34

Rentabilidad por dividendo

2.33

Margen de beneficio

32.947

Empleados

76,302

EBITDA

4.2B

40B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+50.18% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.33%

2.39%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

19B

305B

Apertura anterior

67.85

Cierre anterior

68.14

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

139 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Novo Nordisk A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 feb 2025, 15:33 UTC

Principales Movimientos del Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

5 feb 2025, 11:53 UTC

Ganancias

Novo Nordisk Outlook Provides Some Welcome Relief -- 2nd Update

5 feb 2025, 08:19 UTC

Ganancias

Novo Nordisk Expects Slowing Sales Growth This Year -- Update

2 abr 2025, 11:25 UTC

Charlas de Mercado

Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

2 abr 2025, 09:27 UTC

Acciones populares

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

31 mar 2025, 12:49 UTC

Charlas de Mercado

Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk

28 mar 2025, 15:11 UTC

Charlas de Mercado

Novo Nordisk First Quarter Earnings Could Disappoint, BofA Says -- Market Talk

27 mar 2025, 13:45 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Wegovy Sales Growth Stalls in U.S. Amid Competition, Reimbursement Hurdles -- Market Talk

24 mar 2025, 10:19 UTC

Charlas de Mercado

Novo Nordisk's Ozempic Drug Faces Declining Sales -- Market Talk

24 mar 2025, 09:08 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

19 mar 2025, 15:54 UTC

Principales Noticias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

11 mar 2025, 15:31 UTC

Charlas de Mercado

Novo Nordisk's CagriSema Trial Shows Disappointing Weight Loss -- Market Talk

11 mar 2025, 14:58 UTC

Charlas de Mercado

Novo Nordisk's CagriSema Results Fail to Impress -- Market Talk

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

10 feb 2025, 12:00 UTC

Principales Noticias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Principales Noticias
Ganancias

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Ganancias

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

5 feb 2025, 13:59 UTC

Ganancias

Novo Nordisk Outlook Provides Some Welcome Relief -- WSJ

5 feb 2025, 12:02 UTC

Ganancias

Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns. -- Barrons.com

5 feb 2025, 11:35 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Earnings Report Should Get It Back On Track -- Market Talk

5 feb 2025, 10:10 UTC

Acciones populares

Stocks to Watch Wednesday: AMD, Alphabet, Novo Nordisk -- WSJ

5 feb 2025, 09:43 UTC

Ganancias

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:47 UTC

Charlas de Mercado
Ganancias

Novo Nordisk's Robust Sales Outlook is Reassuring -- Market Talk

5 feb 2025, 08:38 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Earnings, Guidance Imply Consensus Upgrades -- Market Talk

5 feb 2025, 08:32 UTC

Ganancias

Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns. -- Barrons.com

5 feb 2025, 08:30 UTC

Charlas de Mercado
Ganancias

Novo Nordisk Sales Guidance Materially Ahead of Expectations -- Market Talk

5 feb 2025, 06:46 UTC

Ganancias

Novo Nordisk Expects to File For First Regulatory Approval of CagriSema During 1Q26

5 feb 2025, 06:45 UTC

Ganancias

Novo Nordisk Plans to Initiate New CagriSema Phase 3 Trial in 2025 to Further Explore Weight Loss Potential

5 feb 2025, 06:43 UTC

Ganancias

Novo Nordisk: 2025 Free Cash Flow Expected to be DKK75B-DKK85B

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S Esperado

Precio Objetivo

By TipRanks

50.18% repunte

Estimación a 12 meses

Media 102.17 USD  50.18%

Máximo 124 USD

Mínimo 90 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

10 ratings

5

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

67.64 / 70.16Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

139 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.